Definium Therapeutics, Inc. (DFTX) Earnings Call Transcript
May 7, 2026
Earnings Call Speaker Segments
Good afternoon, everyone. My name is Gita Jain, and I serve as Head of Investor Relations. We appreciate you being with us for Definium Therapeutics' First Quarter 2026 Financial Results and Recent Highlights Conference Call. <<operator_script>> You can watch this webcast live in the Investors portion of Definium's site at definiutx.com, and once it concludes, a replay will be made available. Today's speakers will be led by Rob Barrow, who serves as our Chief Executive Officer, and he is joined by Dr. Dan Karlin, our Chief Medical Officer; Brandi Roberts, our Chief Financial Officer; and Matt Wiley, our Chief Commercial Officer. On this call, we will be presenting certain forward-looking statements, which include, without limitation, statements regarding the possible safety, efficacy and regulatory and clinical progress of our product candidates, our anticipated cash runway and our future expectations, plans, partnerships and prospects. A variety of risks could affect these statements, such as shifts in market conditions and challenges related to research and development and regulatory approval processes; these risk factors, along with others, are set forth in the documents filed with the SEC and the applicable Canadian securities regulators, including our annual report on Form 10-K and our Form 10-Q filed today. Forward-looking statements rest on management's assumptions, opinions and estimates as of the date such statements are made, including the nonoccurrence of the risks and uncertainties are described in the filings made with the SEC and the applicable Canadian securities regulators or other significant events occurring outside of Definium's normal course of business. Please be advised not to place undue reliance on these forward-looking statements, which are made as of today, May 7, 2026. Definium disclaims any obligation to update such statements even if management's views change, except as required by law; with that, let me turn the call over to Rob.
Thanks, Gita, and I appreciate everyone being here today. For Definium, the opening quarter of 2026 represented a robust beginning to what we expect to be a defining year. Our attention stays squarely on executing with discipline as we've pushed our late-stage clinical programs forward, gotten ready for several data readouts coming up soon, and kept assembling a remarkable team to steer our eventual commercialization work. During our Investor and Analyst Day a few weeks back, we noted that Definium is now moving into a stretch of considerable clinical momentum. DT120 ODT, our foremost program, continues to progress with 4 Phase III trials currently running in major depressive disorder, or MDD, and generalized anxiety disorder, or GAD, and we anticipate top line results from Emerge later in this quarter, with Voyage and Panorama to follow in the third quarter. The way our Phase III programs are built, they assess outcomes that we think would amount to a significant step forward for patients and for physicians working in psychiatry. Those outcomes encompass not just how much symptoms improve, but additionally safety, tolerability and how long a response lasts after just one dose — aspects we see as essential to setting DT120 ODT apart within the current treatment landscape. We also take encouragement from growing awareness of the substantial unmet need in these conditions. With 3 Phase III readouts expected across 2 of psychiatry's biggest indications, Definium stands at a crucial juncture for our company and for the patients we hope to serve; having secured breakthrough therapy designation for DT120 and GAD, we've built a productive working relationship with FDA, and we intend to proceed as swiftly as we can toward an NDA submission, assuming the pivotal data come back positive. Past our current Phase III efforts, we intend to broaden DT120 ODT's development into further indications, among them post-traumatic stress disorder, or PTSD, with our Haven study slated to begin in 2027. In our view, that's a key chance to further capitalize on what DT120 can offer across areas with substantial unmet need. On the whole, we keep believing that DT120 ODT has the makings of a best-in-class product candidate — one capable of helping reshape what's achievable for the millions of individuals dealing with depression, anxiety and PTSD who existing treatments still fail to serve. At this point I'll hand things to Dan, who can walk through our clinical programs in greater detail. Dan?
Appreciate that, Rob. I want to walk everyone through where our clinical programs currently stand, concentrating on the present status of each late-stage trial and the way those trials were built to measure what we regard as a clinically meaningful outcome, and I'll begin with DT120 ODT. Our lead candidate keeps moving forward through Phase III research in major depressive disorder, generalized anxiety disorder, and now post-traumatic stress disorder. With Emerge, the initial Phase III trial in MDD, we've finished enrolling, with 149 participants. We're in the closing phases of running the trial and getting the data ready, and we still expect to share top line results before this quarter ends. Turning to GAD, we're moving quickly toward top line readouts from our 2 pivotal trials, Voyage and Panorama. Voyage has finished enrolling, with 214 participants. In Panorama, we've gone past our revised target of 200 participants and anticipate wrapping up enrollment during this month. Our expectation remains that top line data will arrive from Voyage early in the third quarter and from Panorama late in the third quarter. Throughout our pivotal program, we've concentrated on disciplined execution, data quality, and consistency across trials and sites; these are sizable, well-controlled studies built to measure how much improvement occurs, along with safety and how long the response lasts after a single dose of DT120 ODT. Because we have confidence in DT120's clinical profile and the substantial evidence gathered so far, our design is uniquely built to demonstrate that one treatment holds its effect for a minimum of 12 weeks. Our Phase III trials in MDD and GAD were originally powered to pick up a placebo-adjusted difference of 5 points. As specified in the protocol design, we carried out sample size re-estimations for Voyage and Panorama. Those analyses happened without unblinding treatment assignments and were meant to evaluate key nuisance parameters, standard deviation and dropout rates, in order to help maintain the intended statistical power. Drawing on those blinded analyses, which took place once half of participants hit the 12-week time point, Voyage and Panorama now carry 99% power or higher to detect a 5-point placebo-adjusted difference, assuming those nuisance parameters stay consistent in the final study analysis; as for Emerge, that trial was powered at 80% to detect a 5-point placebo-adjusted change, with statistical significance anticipated at a little over a 3-point difference under certain nuisance parameter assumptions; we chose that level of power deliberately, since we believe a 3-point or greater difference marks an appropriate threshold for clinical meaningfulness in MDD. Another point worth mentioning is that Emerge uses a 6-week primary endpoint, versus 12 weeks for Voyage and Panorama, which lowers the risk of a higher dropout rate in the primary analysis. On top of that, even though the trials were powered to detect a 5-point difference, we believe a placebo-adjusted improvement of 4 points or more at 6 to 12 weeks following treatment would stack up well against currently available GAD and MDD treatments and other product candidates in the psychedelic category. For psychedelics, one dimension that matters especially is how long effects last. In our Phase II GAD study, a single 100 microgram dose of DT120 showed durability out to 12 weeks. Our Phase III trials are built to assess response consistency and how long it persists as time goes on. In Part B of those studies, patients are tracked for as long as 1 year, and we think that will yield valuable insight to support potential labeling, such as how often retreatment might be required. In addition to DT120, we're eager to move forward with our Phase II trial of DT402 for autism spectrum disorder, or ASD. DT402, the R-enantiomer of MDMA, has demonstrated encouraging prosocial benefits alongside a tolerability profile that could prove favorable. We're developing DT402 to go after the core traits of ASD, in particular the social communication difficulties that sit at the heart of living with this condition. We view this program as a major opportunity, given the substantial unmet need, the rising prevalence of ASD, and the absence of any FDA-approved therapy that directly targets these core traits. Looking forward, the coming 5 months mark a major culmination of careful trial design, rigorous execution, and years of effort aimed at some of psychiatry's most urgent unmet needs. With several Phase III readouts on the horizon, we think we're well placed to produce decisive data on DT120. With that, I'll hand the call to Matt to cover our commercial strategy and the wider treatment landscape. Matt?
Appreciate that, Dan. I want to take a few minutes to walk through what the commercial opportunity looks like for DT120, and I'll build off the material we presented during our Investor and Analyst Day back in April. As we laid out then, GAD and MDD are both enormous markets that have gone underserved for a long time. A lot of the treatments on the market today run into limits — slow onset of action, efficacy that's only partial or inconsistent, and tolerability problems that lead to patients stopping treatment at high rates. Within that overall picture, about 4.2 million adults in the U.S. have gone through 2 or more therapies without getting lasting benefit, and that group sits right at the heart of where we're focusing our initial launch. Our view is that these patients, along with the physicians who treat them, are actively seeking a next-generation choice — one with a different mechanism that can produce durable improvement without requiring daily dosing on a chronic basis. To give a sense of how big this could be, if we use Spravato's average annual price as a proxy, then winning just 1% of the total addressable market across these indications would point to an annual revenue opportunity of roughly $2 billion. Our targeting model was designed around that substantial unmet need; we've pinpointed high-volume health care practitioners — mainly psychiatrists and psychiatric nurse practitioners — who handle concentrated groups of these specific patients. Those high-volume prescribers work inside psychiatric practices, behavioral health networks and select integrated health systems, which is where these patients most commonly get their care. We've mapped out these priority targets thoroughly and intend to concentrate our launch efforts on connecting with these clinicians, especially any who've had experience with, or shown interest in, novel in-office interventions, and who are backed by care teams able to monitor patients through the dosing day. Our belief is that this approach lets us reach a meaningful number of appropriate patients right from the start, while also laying a strong foundation for scalable adoption. One thing we emphasized at our Investor and Analyst Day is that clinician awareness of DT120 keeps growing. Through our ongoing engagement, we've observed rising familiarity with its clinical profile, plus strong interest in it as a possible new option that could help patients get past therapies that no longer deliver adequate or lasting relief; we also presented data showing a high rate of discontinuation on current treatments, frequently because of insufficient efficacy or tolerability. Those difficulties are particularly acute for patients who've already been failed by 2 or more prior therapies, which only reinforces how big the opportunity is for differentiated innovations such as DT120. These realities shape our commercial strategy; our focus is on introducing this therapy in a manner that's scalable, accessible and practical in real-world care settings, with no need for chronic interventions. A central piece of our planning is a centralized hub support model along with additional field support, so that adoption and delivery can proceed without friction. At the same time, we're continuing to talk with physicians, payers and other stakeholders so we can better grasp the decision drivers involved in adoption, patient identification and reimbursement frameworks. We've combined a clearly defined unmet need in a market that's receptive with our disciplined, patient-focused commercial approach, and because of that, Definium is in a very strong position as we get close to pivotal data readouts and move DT120 forward toward a possible commercial launch. With that said, I'll hand things over to Brandi so she can walk through our financial results.
Thanks, Matt. Before we walk through the financials, I want to briefly explain our thinking on capital deployment right now, since this is an important stretch for Definium. As we entered 2026, we were confident that our financial flexibility would let us move ahead on several critical efforts simultaneously — continuing Phase III execution, getting ready for the NDA, addressing market access, and maintaining dialogue with key opinion leaders and top practitioners. These investments are meant to bolster our path forward and, if DT120 wins approval, ensure the company is positioned to carry out a strong, well-considered commercial launch. Another positive sign in 2026 has been the way our investor base kept developing, with solid participation from people already holding shares and rising curiosity from newcomers as our programs moved forward; in our view, this shows both a widening appreciation of what lies ahead and trust in how carefully we manage execution and deploy capital. Moving on, I'd like to discuss our Q1 2026 financial results, which you can find fully laid out in the earnings release that went out this afternoon. R&D costs came in at $41.5 million, up from $23.4 million in Q1 2025. We saw a net rise of $18.1 million, mostly from a $15.2 million bump in DT120 program expenses, $3.2 million more in internal personnel costs tied to growing our R&D capabilities, and $0.3 million in DT402 program expenses—partly offset by a $0.6 million decrease in preclinical and other program expenses. General and administrative expenses came to $17.7 million in Q1 2026, versus $8.8 million in Q1 2025. We saw a net rise of $8.9 million, driven mainly by higher stock-based compensation expenses, which went up $3.9 million, along with a $1.4 million increase in personnel-related expenses, a $1.4 million increase in commercial preparedness related expenses, a $1.4 million increase in corporate and government affairs expenses, and a $1.2 million increase in legal and patent expenses. Those gains were partly offset by a $0.4 million decrease in other miscellaneous administrative expenses. This year-over-year growth in G&A expenses reflects intentional investment meant to support a more mature organization as we get ready for our anticipated Phase III top-line data readouts and potential commercialization. On the whole, our R&D and G&A expenses for the first quarter matched our internal expectations, and we continue to make meaningful progress across the DT120 and DT402 programs. For the first quarter of 2026, we reported a net loss of $77.1 million, up from $23.3 million in the same quarter of 2025. Just to remind everyone, swings in the fair value of the 2022 USD financing warrants we hold — which get marked to market every quarter — can have a big effect on our net loss. In Q1 2026, that fair value change added $20 million to the net loss, driven by our share price rising from $13.39 on December 31, 2025, to $18.90 on March 31, 2026. Now let's look at the balance sheet. We closed Q1 2026 with $373.4 million across cash, cash equivalents and investments, and we think that capital base gives us enough runway to fund our planned operations through several expected clinical readouts and on into 2028. The year 2026 looks like it will be one with abundant data and real strategic significance for Definium. Because of where we stand financially, we can keep our attention on executing with discipline, while also preserving the room we need to back our priorities and go on creating value for shareholders over the long term. With that said, I'll hand the call back over to Rob.
Appreciate that, Brandi. Following a long stretch of careful trial planning and disciplined implementation, we're now arriving at a stage filled with many pivotal milestones that, in our view, will shape the coming era for Definium within the wider sector we operate in. With mental health awareness month upon us, the pressing need to bring forward novel treatment choices and the duty we hold toward patients comes through with particular force. Prior to wrapping up, I'd like to express gratitude to our remarkable team, the investigators along with their teams, and the hundreds of patients whose efforts turned this work into reality. Having said that, we welcome your questions.
Your audio dropped for a moment there. I'm Emily, filling in for Paul Matteis from Stifel, and this is directed at Paul. Our question is quick: if you achieve positive results in MDD and anxiety during this year, might you expand on your perspective regarding the volume of long-term safety and retreatment information that would be necessary to secure approval? Also, within that long-term information, would a patient have to be retreated for some specific duration before it qualifies as long-term exposure for safety purposes?
Wonderful. Yes. Many thanks, Emily. I'll touch on this quickly, then hand things to Dan, who may go into more detail; across the last several years we've enjoyed an excellent ongoing conversation with FDA, and clearly we're building toward a future strategy for NDA submission, so the favorable results and everything else simply need to occur so we can be prepared for an NDA, and we're positioned extremely well for that. Regarding safety information and what is needed, we're quite at ease following Part A's completion and with the information that will be on hand when we file, plus the different milestones along the way; our safety exposure is adequate, covering both single dose and extended timeframes. Naturally, the intriguing aspect of medicines that don't require continuous, daily, or very short fixed-interval dosing—unlike the therapies available now—is that treatment patterns differing among patient groups or among individual patients can result in 6 months of treatment appearing as a single dose or as several doses. Thus we're quite eager to characterize this, naturally, within our Phase III program. Even so, we believe our positioning is very strong given the studies we're running, and we'll be in excellent shape to proceed. So, we have favorable Phase III data. Dan, would you like to provide any additional perspective on that?
Yeah, so perhaps I can add just a small amount of detail regarding one aspect of the worth of the Part B portions of these trials, in which we can provide triggered treatment when patients show moderate symptoms of GAD or MDD or worse—moderate or severe. The benefit there is really several things. First, it helps retain participants in the Part A portion of the study, as you saw from the sample size re-estimation outputs we announced; our dropout rates are strikingly low, partly because individuals understand they have this chance to receive open-label treatment in Part B if they remain ill. Being able to track subjects over the long term, for as long as a year following their first blinded dose, is another plus of these trials, correct? So for those who reach mild illness or better, we simply continue observing them in that original controlled blinded state unless they become sick again, and until they become sick again, if that does occur. So that's yet another benefit. And then, as Rob mentioned, in those Part B portions, we can provide as many as 4 more open-label treatments, depending on whether patients develop moderate illness or worse. That will let us begin to really meticulously describe, across these studies, the treatment patterns that arise when treating individuals with moderate or worse symptoms, which aligns quite closely with what we believe would probably occur in the real world, should approval come. So with all of that data available, we're confident we'll have everything required both to inform FDA and, naturally, to inform the clinical and patient community if approval is granted.
So a few things from my side. First, when it comes to how patients go through this — specifically monitoring — how sure are you that, once this is actually happening, a single dosing session monitor will suffice for keeping an eye on patients? That's the first one, a REMS-type question, I suppose, on that topic. Then second, I'd like to ask about the PTSD Haven study. If possible, give us a bit of detail on what led to the decision to conduct Haven as a straightforward active versus placebo trial, rather than having a low 50-microgram dose arm included. I'd really like to hear your reasoning there.
Thank you, David. Sure, Dan, I'll hand it back to you.
Absolutely, that's a good question. The way things stand with the clinical trials is that, following FDA guidance, there's a lead monitor present in person along with a second monitor who is able to observe remotely by video. That has been the requirement for running these trials under FDA instruction. From start to finish of the studies, we've done everything possible to gather regulatory-grade data regarding the work those monitors perform, so as to offer support and reassurance to patients, including data on what the function of that second monitor ultimately turns out to be. The purpose behind all of this is to build the argument that a single monitor is definitely something that ought to be permitted in actual practice. That's where we stand. Looking further out, when you consider other treatments that produce rapid changes in consciousness, matters such as monitoring ratios have not been spelled out in explicit terms. Ultimately, clinical discretion and clinical judgment have been relied upon to make sure patients receive safe monitoring. Naturally, certain elements exist within current REMS, and we anticipate that our REMS will include elements pertaining to monitoring. However, the evidence we're gathering as we go aligns with the evidence we've managed to establish regarding what defines safety and efficacy. I could also speak to PTSD if you would like, Rob?
Absolutely, that would be wonderful.
Of course. Now, across the entire Phase III program, we have studies that are pooled together, is that right? Some of those studies involve 2 arms. And twice, we added that confounding arm with lower enrollment at 50 micrograms, correct? That arm isn't one we analyze — it's not an arm where we care about how the 50-microgram drug performs. What those comparison groups actually did was muddy the picture for participants in the other groups about what treatment they'd gotten. So for both GAD and MDD — the first trial we ran in each of those indications — the design had two arms and used an inactive placebo. Our view hasn't changed that this is the right control to use when studying psychiatric drugs, whether that's DT120 or any other psychedelic. That's the approach we took in PTSD as well. In our view, nothing beats a head-to-head comparison when you're trying to demonstrate efficacy. We're pulling together what we've learned so far, and once we can read out results from the three additional studies we're running, and eventually from Ascend—which, per our guidance, is getting underway very soon—all of that evidence will build up and help us figure out how the 50-microgram dose arm may influence what participants in the other arms believe about their own dose, that is, whether they think they received an active treatment dose, and whether that belief shapes the outcomes we measure. As we learn more and gather additional data on how these various trials perform under differing control and compounding setups, that's going to shape how we approach upcoming trials and their design. That said, when it comes to the main proof of efficacy, our position remains that head-to-head is the appropriate control condition.
Andrew Tsai, this is Brian Castiglioni, and I've just got two items. The first one concerns how patients move through treatment. In your remarks, Phase III was described as a 5- to 8-hour journey for patients, while Phase II ran as long as 12 hours. What is it that gets you closer to that 5-hour mark instead of 8? And what would you need to lock down with the FDA incentives in order for that to happen? The second item is about how subjects on placebo respond. In your Phase II GAD trial, the placebo response was actually quite elevated compared with other GAD trials. What direction do you think placebo goes in the Phase IIIs? And the same question holds for the Phase III MDD trial as well.
Yes. Thanks, Brian. So, on that first question about the criteria and a few of the adjustments — we actually flagged this during our event a couple of weeks ago. There are two things. One is the formulation: in our Phase III program we're using an orally dissolving tablet, and since we see absorption happen more quickly with it, our thinking is that this could lead to a better profile when it comes to how the symptoms resolve. The other is the way we went about this — it was intentional right from the start. When we were heading into our phase II program, what we had to work with was limited information about what the safety requirements would actually be and how monitoring would work in those studies. So in phase II we put in a higher dose — the 200 mcg dose. So we took a cautious approach—and I think appropriately so—by stretching out the observation window in phase II to 12 hours, and we had a really extensive list of criteria we were tracking to determine when a patient could stop being monitored. Drawing on what we learned and the data that came out of that phase II trial, we adjusted things—not just the formulation, obviously, but also the process, that checklist we rely on. Going into phase III, we're pretty confident we'll be heading toward something shorter. That's definitely the pattern we're observing up to now. So, taking into account that the shift from requiring 12 hours of monitoring to 8 hours for everyone enrolled in the trial came about because of conversations with the FDA and was supported by the data, I'd say we're pretty confident we're moving in the right direction. Even so, what we observe inside that window is a very compelling clinical profile — one where patients aren't being cycled through and pushed out quickly, and where providers get low turnover along with efficient, high-throughput care for those patients. On your second question about placebo response: you're correct in pointing out that our phase II study showed an unusually strong placebo response. Let's zero in on the GAD symptoms, or the HAM-A scores for GAD, for a second. What we found — and you'd see this same pattern with any modality, on practically any scale — is that when there's an 80% chance patients are receiving at least some of the drug, that tends to drive the placebo response higher. On top of that, we saw that about a third of the people on placebo thought they'd been put on drug. And with several lower doses in the mix, that likely makes the placebo effect even stronger. There are further factors involving patient dropout, since in Phase II we had nothing to give patients past the initial dose, whereas in Phase III we now have part B, and patients are assured open-label drug access provided they remain through the study's 12 weeks. In our view, all those factors contributed to what happened in Phase II. When we consider the Phase III program, a reduced allocation ratio plus giving patients an incentive to remain in the study ought to bring things down to, and possibly under, the historical averages for placebo response. We would anticipate that holding true in both GAD and MDD. I believe we observe this in other programs too; we examine other trials within our category. We examine the pivotal trials for Spravato; the placebo responses there appear lower than what we have historically witnessed for antidepressant daily drug studies. It would not shock us to see a placebo response below average throughout the Phase III programs here. Yet since we surpassed such an elevated placebo by such a broad margin in Phase II, we feel, as you know, very confident regardless that we will be positioned well as we approach the Phase III data.
Basma here, filling in for Marc. We appreciate you giving us the chance to ask. To start, we'd like to ask about the PTSD program. Could you walk us through once more what you believe about the dose for PTSD? What makes you confident it will work? And could you also go over the assumptions behind the study's power? Then our second question: for the MDD submission, or the GAD, whichever comes after, do you figure you can rely on the safety data from the GAD, or will you need to gather a separate set of exposure data in the appropriate patient group? That's all from us.
Let me handle the second one first, then I'll pass it to Dan. As you know, we definitely anticipate having exposure from pivotal trials and efficacy trials in whatever population we're studying, naturally. ICH guidelines don't get specific about patient exposures, and they aren't tied to a particular disease or disorder. You'd certainly anticipate a large population requirement, like what you get from ICH E1 or similar. Dan, I'll hand the other one over to you.
Absolutely. That's a terrific question regarding PTSD. After completing our phase II dose range finding study, we gained strong confidence in the phase III dose, as well as the dose in this formulation, through transitional PK work we conducted. That gave us the assurance to move ahead in GAD and MDD. As you mentioned, it also gave us confidence to proceed in PTSD with that same dose. We have every reason to believe that from a symptomatic standpoint, from the perspective of overlapping disease definitions, and from the standpoint of overlapping scales, all of these align. There's no real basis to expect that the differences creating these separately defined conditions — which nonetheless share such enormous overlap — would necessitate any further dose adjustment going forward. We enter PTSD with the same confidence we brought to MDD, using the dose we initially chose for patients with primary GAD. On the powering side, we keep viewing something like a 5-point change on the scale as an excellent sweet spot to target. We continue to think about that across the scales, whether it's the HAM-A for GAD, the MADRS for MDD, or the CAPS for PTSD.
When it comes to this overlap, I'm hoping to get a clearer picture. MDD strikes me as having more of an episodic nature, whereas with GAD — thinking about the likelihood of the trials succeeding, or whatever the case may be — do we feel greater confidence in one condition compared to the other? Along those same lines, could something inherent to GAD as a disease lead to a larger placebo effect, or does it stem more from how the trial is designed, as you suggested?
Thank you very much, Franc. I'll hand that question back to Dan too.
That's a terrific question, Franc. We've expressed this in several ways, and clearly we've added some new slides to the deck now to examine the GAD MDD overlap. As you pointed out, for the overwhelming majority of patients it's genuinely something of a timing-based separation — these are individuals who, you know, if they carry an MDD diagnosis, it's because they've either experienced or are presently in a major depressive episode. Major depressive episodes, by definition, conclude; they possess beginning and ending points, while GAD is really best understood as that foundational, ever-present anxious backdrop. What we do understand is that the longer a person endures elevated anxiety, the greater their odds of experiencing a major depressive episode. The more major depressive episodes, and the more intense those major depressive episodes, that people endure, the greater their odds of carrying elevated anxiety levels in the background. When it comes to probability of success, that's a genuinely fascinating question. Historically, for every class of antidepressant, MDD has proven an easier target than GAD using those very same antidepressants. Partly, that's because with MDD, we're helping people return to a state they occupied if not lately, then at least relatively recently within the last, you know, 1 year or 2 years at most, and frequently far more recently than even that. It resembles resetting a state the person will return to and has occupied more recently, while GAD represents more of a shift to a state someone likely hasn't occupied in quite a while, given how longitudinal the disease is. MDD has historically been an easier target, and that partly is what gives us great confidence. We also, of course, observed in phase II that we could move the MADRS quite dramatically in the GAD patients we were treating, even though they were beginning lower than we would ordinarily start people in an MDD study. Which means, of course, there's less room on the scale for movement, and we still observed quite a bit of movement. All of that combined continues to give us real confidence in our MDD studies. As for placebo and GAD, that probably isn't what's at play here. I think that, as Rob already addressed here and as we often discuss, the design of that study both produced a higher actual placebo response with 5 arms or active, and the likelihood of receiving drug being so high will drive an actual higher placebo response, particularly since there are these lower dose arms that may or may not feel like something to someone, so people on placebo could very easily mistakenly believe they were on drug. Also, with the dropout rate and the data replacement strategy, taking that already actual high placebo response and making the measured placebo response actually overrepresent the background real placebo response. That likely has more to do with cause than with the condition itself.
Thanks for that. Perhaps I could quickly come in with Matt. Matt, you mentioned something earlier that you folks have brought up before — could you just assist us in grasping it, since we don't often hear about it — a 1% penetration of the TAM works out to roughly $2 billion. Could you help us get a handle on how that TAM — how do you account for the MDD and GAD overlap when arriving at that figure? And on the commercial front as well, could you just help us, you know, jog our memory on what we've learned regarding the J-code consequences for Spravato and how that could have spurred sales? Thanks.
Certainly. That figure of 4.2 million patients I reference does include any patients who have both; these are unique patients we have identified. All of them are patients 18 and above; that represents the true TAM. We have factored in any of the overlap. If someone has a dual diagnosis, they get deduped; as for the J-code for Spravato, I believe what it accomplishes is giving us solid confidence that a path exists to submit for a J-code for DT120 too; that has been part of our plans, and it's an operating assumption to submit once we reach the market if DT120 gets approved.
Nice work on the quarter. Regarding the MDD OLE, the redosing trigger was set at a MADRS score of 20 or above. Can you help us get why 20 was the figure picked? Based on your market research, is that severity level a cutoff at which healthcare practitioners would probably advise patients to have another dosing session?
Many thanks. I'll hand things to Dan too.
Yeah, that's a really good question, Samantha. What we chose to do throughout our studies, in the part Bs, is to place the cutoff on the scale right at the dividing line separating mild from moderate. There are a few of them. Of course, with any of these scales, that choice is kind of arbitrary, isn't it? The people who design the scales select numbers, those numbers undergo psychometric testing and validation, and to some degree they end up as the thresholds for as long as the scale exists. We found the boundary between mild and moderate especially compelling because, absolutely, when you talk with the broad community of prescribers and treaters out there, that really does look like the point where people would think about even using medication at all, never mind something more intensive and probably more costly. That cutoff also lines up with an intriguing shift, one that's a bit less tied to the scale, but the practical fact is that when we consider mild as opposed to moderate illness, moderate is the stage where functional deficits begin to pile up, where the disorder's symptoms grow severe enough to get in the way of life's activities, of daily living activities, whether that's school, work, family, anything. To us, that looked like a sensible spot to draw the line in the studies and a threshold likely to be used in clinical settings, although it would definitely not be a threshold clinicians would have to follow. Naturally, when all is said and done, clinical judgment governs everything. Given how intensive they are to administer, these scales don't get used much in clinical practice. What we expect will occur with actual prescribers, based on the discussions we've had with them, is that if their assessment finds someone has functional deficits caused by their disorder, that will strongly nudge them toward using therapies like ours.
One more point to add for context, Sam: sure, there's plenty of talk about the different subgroups within MDD and about patients who previously didn't respond to SRIs being treated as if they were a distinct group. But what we actually observe — in patient experience, in health economic results, and in everything that truly creates value personally, functionally, and economically — is that severity is what improves. We identify people with severe symptoms and bring them down to a point where that functional impairment gets meaningfully better; that's the reason we placed the treatment threshold where we did. It's also the reason we concentrate so heavily on examining how severe these populations are, instead of isolating ourselves inside a tiny slice of the population that simply failed to respond to 2 prior SRIs.
Got it. If I could just slip in a final question; as interventional psychiatry keeps getting woven more and more into practices and healthcare systems, what kind of groundwork is happening at clinics so they can shift and actually deliver DT120 in practice? Perhaps what are you picking up on while you do your commercial prep work?
Matt, I'll hand it over to you.
Appreciate that, Sam. From the clinicians we talk to — particularly the ones who currently handle a large amount of intervention work — the message is that they've been getting ready for psychedelics to reach the market, and they're setting aside room for it. The anticipation out there, plus how open the market is to these interventions as they arrive, leaves us feeling fairly encouraged. There's definitely a lot of excitement around DT120, and some of the data we presented only a couple of weeks back, I'd say, truly underscores both the momentum and the market's willingness to embrace this. Every one of those dimensions gives us encouragement, and we're of the view that our targeting model genuinely assists in putting first those physicians who are, A, open to the drug concept and, B, possess the ability and the room to take on these patients for treatment.
Congratulations on everything you've achieved. I appreciate you fielding our questions, and once more for having us at your event 2 weeks back. It was quite informative, and we're truly grateful. What we wanted to ask is, when you speak with clinics, what economic incentives exist for them to adjust capacity for DT120, particularly when you set Spravato aside? If you regard time-based reimbursement and reduced friction from patient turnover relative to Spravato as possible benefits, and maybe if you could estimate how many clinics would ultimately be needed to treat 100,000 patients per year, based just on probable capacity, we would be very thankful.
Yes. Thank you for asking. Regarding the economics of a practice, we certainly understand that this is foremost in physicians' minds, and we're currently working out clear guidance on what will be offered at launch as well as those codes we aim to obtain after launch, ensuring physicians get proper reimbursement for administration. I believe the manner in which clinics have approached this, at least initially, has been to set aside a certain amount of space, and then they expect to assess the market and assess the volumes arriving in order to decide if they should dedicate more space at their clinics. This is really something that will be settled once we enter the market. As we get nearer, we'll be able to share far more market research about what we believe that volume and capacity will look like, both in market and afterward, in the years that follow.
Just one more quick question regarding PTSD — could you discuss what sets DT120 apart from other psychedelics, psilocybin and DMT, particularly for that indication, keeping in mind the different symptoms involved? If you have any thoughts or conversations with the VA, given how common this is among veterans there, whether that shapes enrollment criteria or any data gathering they might have interest in, I'd really appreciate it.
Thanks a lot, Matt. Dan, would you like to handle that one?
Sure, glad to do that. Okay, we're live now — unmuted. A point that comes up frequently from sites regarding what DT120 is like and how patients respond to DT120 is that it's tolerated extremely well, especially on an emotional level. People report that the way the drug begins, how it acts, while it's at that sort of plateau effect, and then the gradual coming back to an ordinary state of consciousness is something they handle well and actually find pleasant in ways that other drugs might not be. Especially for individuals with, you know, significant anxious arousal, that's likely a positive, correct? We want people who are especially sensitive to what's around them and sensitive to that kind of hypervigilance that occurs with PTSD to go through that kind of experience, to have a gentle and predictable experience that gives them both the time to have the experience they're having while at the plateau, and also to have that onset and offset be predictable; we believe that genuinely represents a differentiated advantage of this drug itself. You know, something I left out was the second part there regarding the VA and, you know, we've been collaborating with VA researchers on our research so far. Naturally, as we enter the PTSD space, we'll keep deepening and strengthening those relationships. Naturally, we're always seeking guidance from experts across the various conditions we work on. The VA's expertise in PTSD is going to be really important for the design and execution of those studies, just as it has been in our studies so far.
I've got three. To start with, what's your current thinking around a filing strategy? Would you submit for GAD and MDD simultaneously, or is your view that GAD, since it will have 2 phase III readouts sooner, becomes the first indication you target? That's my first one.
Yeah. Thanks, Sumant. As you know, we're clearly engaged in a lot of dialogue with FDA and have been regarding the right approach there. I think what we've naturally also observed is a great deal coming from FDA regarding its thinking on filings for studies where overlap is substantial. There exists a lengthy regulatory and legal precedent, in cases of highly overlapping indications, for one single study to support expansion into that indication. As you know, clearly part of that will depend on how compelling the data turn out to be across the studies and especially in MDD, correct? If a smaller effect is what we see, then obviously the evidence is less compelling than if we're observing an extraordinarily large effect, which would suggest, you know, fairly small studies would be needed to replicate it. Ultimately, some of this will be informed by the data and by later discussions with FDA, but our confidence in the position for filing DT120 is quite strong. Whether that gets filed concurrently or sequentially, we believe we'll be well positioned to pursue both these markets, hopefully, as we enter the market and reach the patient population, if we're lucky enough to have a drug approved.
Understood. Appreciate it. Now, turning to Matt regarding commercialization — GAD and MDD both offer enormous potential, but in your view, which of the two might turn out harder to conquer for DT120, and what makes you say that?
Thank you, Sumant. Here's how we see it: the unmet need in each of these indications is significant, and our market research shows strong receptivity for both. Our targeting model and our value proposition are designed with both indications in mind. We don't play favorites, honestly. There are plenty of patients in need of help and in need of this treatment, in our view. Should approval come, we intend to pursue both markets equally, assuming we secure a dual indication. Another thing to remember: GAD doesn't show up in claims data the way MDD does, purely because no novel treatments have emerged for a couple of decades. We're confident there's a substantial amount of GAD that goes inadequately diagnosed in the ICD-10 data, and we expect that to shift once a therapeutic intervention addressing that need arrives.
Okay. The final item is, maybe, a somewhat philosophical one. What benefits and drawbacks actually exist in practice when you get a commissioner's national priority voucher?
Yeah. Thank you, Sumant. That's a solid question — first, obviously, whatever helps us speed things up and work more efficiently on development is something we'd definitely be open to exploring. That's the reason we've moved at truly breakneck speed; we filed this IND roughly under 4 years back. Our pace of development has been remarkable. Those aspects are within our control, and we can devote all our hours and energy and conduct the research properly to push the program toward pivotal data, which is arriving quite soon. Regarding what follows, clearly with novel programs and the FDA, there can be benefits. There are also possible downsides. One factor that's especially important for our program, I'd say, is the chance to potentially pursue both of these indications. Should we find ourselves in that situation, a great deal is being worked through concerning whether one or the other, or both, might gain from something such as a CMPV. Of course, we've witnessed certain positives emerge from that. We've also observed certain risks tied to it. We'll maintain our strong dialogue with FDA and keep seeking ways to accelerate wherever possible. At present, obtaining the data and moving as efficiently as we can from there toward an NDA application is our focus.
Nice work on the advancement. Now, on the Emerge data readout, I'm wondering — what level of detail will you provide on how long patients take until discharge? And if someone runs a bit past that 8-hour mark, could you still get approval with an 8-hour treatment window? Thanks.
Yes. Thank you, Chris; we pay very close attention to every detail in all our work and aim to nail down precisely every key feature of these trials. That's how we'll approach it as well when it comes to how we have been reviewing the end-of-study checklist and determining when it's appropriate to clear patients from monitoring. Naturally, with those dynamics, we'll examine all of it — from averages to adverse events to each individual patient, plus anything else that might prove valuable. It's going to be something we're very focused on, and we're genuinely thrilled about the prospect of sharing some findings from it.
This is Arabella, sitting in for Patrick. Many thanks for taking my question. Now that the DEA can reschedule following a successful phase III, how much time does that really stand to save in practice? And how do you plan to start those discussions once the data comes in? I also wanted to ask whether you could say something about DT402 in ASD, and which metrics or signals you'll be watching to advance that program. Thank you.
Thank you, Arabella. What you're referencing, I believe, is the executive order President Trump signed saying the DEA ought to review its scheduling assessment once phase III data exists, rather than waiting until FDA approval. Were that put into practice as written, and were the DEA therefore able to reach a scheduling decision concurrently with an NDA approval, the savings could be 90 days — that being the current timeframe needed to arrive at an interim final rule and the issuance of a schedule for the product once approved. There's a genuine opportunity here, and it's something we've actually been quite involved with for some time, looking at ways not to cut any corners but to make the process more efficient and strengthen cooperation among agencies in the federal government, so that the stretch from FDA approval to patients actually obtaining the drug becomes as brief as it can be; given how enormous the need is and how big the chance to meet that need is, we shouldn't be losing any days we don't have to in getting these drugs to patients. That prospect has us quite enthusiastic, and we keep having excellent dialogue with FDA, with CSS at FDA, and whenever possible with DEA. On your second question, I'll hand things to Dan for a quick word on DT402.
Absolutely. I appreciate the question about DT402. It's a topic we're glad to discuss. Like we've mentioned previously, we are running a rather compelling efficacy signal trial in ASD. To capture that over the span of a single day, we've put together a collection of assessments that can be administered multiple times within that day, correct? This lets us examine what happens before a dose, shortly after dosing begins, later in the dosing period, and once more as the drug's effects diminish. For this purpose, we've built instruments that may be somewhat leaner than what you'd typically deploy for a regulatory submission, yet they still contain the elements of those tools—you know, the construct elements of those instruments—that can be posed at reasonable speed and on a repeated basis throughout the day; we have patient-reported outcomes, clinician observation outcomes, caregiver observation outcomes, plus certain digital markers, some novel digital behavioral markers examining things such as voice, facial expression, and eye tracking, all incorporated into what amounts to a quite intensive dosing day, with as many distinct measures as we could feasibly squeeze into that dosing day while keeping the patient experience comfortable.
What volume of data are you looking for from part B of the trials, where you're looking at the duration until patients take that second, third, or 4th dose, before you file for approval and can inform the label's retreatment circumstances? And what amount of data do you figure you need to hold talks with payers regarding coverage and pricing? My second question concerns market capacity given how many clinics exist right now. To truly reach the peak potential, how much growth do you believe is necessary in terms of clinics in the U.S.
Thank you, Ami. We definitely feel solid about where we stand as we get close to top-line results and receive the part A data. It's useful to point out quickly that when it comes to earlier drug clearances, particularly for antidepressants, where there are plenty of precedents, most of those medications win approval on the strength of short-term trials, with commitments after marketing to conduct lengthier chronic research. In this manner, we're expanding the limits of what a short-term trial is capable of. With just one dose, we track patients across a 12-week period, and in generalized anxiety disorder, that 12-week mark serves as the primary endpoint. You know, people suffering from GAD don't just get better on their own in a meaningful way over 12 weeks. That's a key piece of why we feel so confident about where we stand with the part A results. Naturally, the part B results will help us understand how often retreatment should happen, how retreatment patterns look as time goes on, what occurs with each subsequent retreatment—everything we're working to map out there. A substantial portion of the part B information is already in our hands. We'll keep pulling that together from every one of our programs for the rest of this year, and also as we move closer to submitting our NDA. On the question of capacity, our view is that many people fail to appreciate just how much of it is available. The amount that can be brought online right now goes well beyond what, in my view, any published model forecasts for uptake. So a bottleneck on capacity isn't something we anticipate. For anyone who joined us in New York a few weeks back, part of the goal is to shed some light and clear up confusion around what it really takes to get a treatment room up and running. If you've got a space, and you're willing to spend a few hundred dollars to make it a bit more comfortable, that can lead to a better experience for patients. If a room allows a person to stay put for an extended period, within a facility that's already providing care, that's enough. From where we sit, there's no real financial or logistical obstacle in the way. People throw around the word infrastructure, but that word implies far more than it should. As we see it, capacity available right now is ample. Going forward, we anticipate considerably more capacity expansion, and our aim is to give patients and providers working in the field the strongest possible backing, enabling adoption and treatment whenever they want it. Our sense is that a strong pull and a strong wish to adopt will exist, covering both treatment centers and patients showing up to receive care.
All right, and thanks to each of you for being here with us today. We have a lot of enthusiasm regarding the upcoming quarters, since 3 crucial readouts are expected during Q2 and Q3. We're eager to present those results when the appropriate time comes. Thanks, everybody.
We appreciate everyone joining us on this call. That brings the program to a close. You're free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Definium Therapeutics, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Definium Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.